References
- Ashurst I, Malton A, Prime D, Sumby B. Latest advances in the development of dry powder inhalers. Pharm Sci Technol Today 2000; 3/7:246–256.
- Newman S P, Busse W W. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96:293–304. [PUBMED], [INFOTRIEVE], [CSA]
- Serra-Batlles J, Plaza V, Badiola C, Morejon E. Patient perception and acceptability of multidose dry powder inhalers: a randomized crossover comparison of Diskus/Accuhaler with Turbuhaler. J Aerosol Med 2002; 5:59–64.
- Bartow R A, Brogden R N. Formoterol: an update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998; 55:303–322. [PUBMED], [INFOTRIEVE]
- Vervloet D, Ekström T, Pela R, Duce Gracia F, Kopp C, Silvert B D, Quebe-Fehling E, Della Cioppa G, Di Benedetto G. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med 1998; 92:836–842. [PUBMED], [INFOTRIEVE], [CSA]
- Steffenson I, Faurschou P, Riska H, Rostrup J, Wegener T. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and albuterol, followed by a 12-month trial with formoterol. Allergy 1995; 50:657–663. [CSA]
- Bensch G, Lapidus R L, Levine B E, Lumry W, Yegen Ü, Kiselev P, Della Cioppa G. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001; 86:19–27. [PUBMED], [INFOTRIEVE], [CSA]
- Molimard M, Bourcereau J, Le Gros V, Bourdeix I, Leynadier F, Duroux P, In association with the French FOR-F-01 Study Group. Comparison between formoterol 12 µg b.i.d. and on-demand albuterol in moderate persistent asthma. Respir Med 2001; 95:64–70. [PUBMED], [INFOTRIEVE], [CSA]
- Keller M, Müller-Walz R, Gilchrist P, Eggimann T, Winnips C. The SkyePharma Multidose Dry Powder Inhaler, 8th Annual Conference on Dry Powder Inhalers, Management Forum Conference E6-1099, London, UK, June 28–29, 1999.
- Dahl R, Creemers J P, van Noord J, Sips A, Thomson M, Cousin M, Fashola T. Similar effectiveness of formoterol (Foradil®) administered via a new multiple-dose dry powder inhaler or Aerolizer® in adults and adolescents with asthma. Am J Respir Crit Care Med 2001; 163(5):A445.
- Chuchalin A, Manjra A, Rozinova N, Skopkova O, Della Cioppa G, Widmer A, Fashola T. Formoterol (Foradil®) is effective in children with asthma when administered via Aerolizer® or a breath-activated multiple-dose dry powder inhaler. Am J Respir Crit Care Med 2001; 163(5):A846.
- Juniper E F, Guyatt G H, Cox F M, Ferrie P J, King D R. Development and Validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999; 14:32–38. [PUBMED], [INFOTRIEVE]
- Pleskow W, LaForce C F, Yegen Ü, Matos D, Della Cioppa G. Formoterol delivered via the dry powder Aerolizer® inhaler versus albutamol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. J Asthma 2003; 40:505–514. [PUBMED], [INFOTRIEVE]
- Sloan J F, Vargas-Chanes D, Kamath C C, Sargent D J, Novotny P, Atherton P, Allmer C, Fridley B L, Frost M H, Loprinzi C H. Detecting worms, ducks and elephants: a simple approach for defining clinically relevant effects in quality-of-life measures. J Cancer Integr Med 2003; 1:41–47.
- Bensch G, Berger W E, Blokhin B M, Socolovsky A L, Thomson M H, Till M D, Castellsague J, Della Cioppa G. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 2002; 89:180–190. [PUBMED], [INFOTRIEVE], [CSA]